This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crumrine, R. C. Articles by Cooper, B. R. Search for Related Content PubMed PubMed Citation Articles by Crumrine, R. C. Articles by Cooper, B. R.

(Stroke. 1997;28:2230-2237.)
© 1997 American Heart Association, Inc.

Articles

Lamotrigine Protects Hippocampal CA1 Neurons From Ischemic Damage After Cardiac Arrest

R. Christian Crumrine, PhD; Kristine Bergstrand, DVM; Amy T. Cooper, LVT; Walter L. Faison, BA; Barrett R. Cooper, PhD

From the Department of Molecular Pharmacology, Glaxo Wellcome Inc, Research Triangle Park, NC.

Correspondence to R. Christian Crumrine, PhD, Department of Molecular Pharmacology, Glaxo Wellcome Inc, PO Box 13398, Research Triangle Park, NC 27709-3398. E-mail rcc41549{at}glaxo.com

Background and Purpose Lamotrigine (LTG) is an anticonvulsant drug whose mechanism of action may involve the inhibition of glutamate release by blocking voltage-dependent sodium channels. Glutamate neurotoxicity may contribute to cerebral ischemic damage after recovery from cardiac arrest. Thus, LTG may prevent the brain damage associated with global cerebral ischemia by reducing the release of glutamate from presynaptic vesicles during the ischemic insult or the early recovery period.

Methods LTG was studied in cardiac arrest–induced global cerebral ischemia with reperfusion in rats. In the first set of experiments, LTG (100 mg/kg, PO) was administered before induction of ischemia; and in the second experiment, LTG (10 mg/kg, IV) was given 15 minutes after ischemia and a second dose (10 mg/kg,IV) was given 5 hours later.

Results In both experiments LTG reduced the damage to the hippocampal CA1 cell population by greater than 50%. Neuroprotection was not associated with changes in brain temperature or plasma glucose concentration. Plasma concentrations of LTG ranged between 8 and 13 µg/mL. Patients taking LTG as a monotherapy for epilepsy typically have plasma levels of LTG in the 10 to 15 µg/mL range.

Conclusions These data suggest that LTG may be effective in preventing brain damage after recovery from cardiac arrest. Patients on LTG monotherapy for epilepsy have plasma concentrations very similar to those found to be neuroprotective in this study. Although difficult to extrapolate, our data suggest that LTG at neuroprotective doses may be well tolerated by humans.

Key Words: rats • heart arrest • cerebral ischemia, global • neuroprotection • sodium channels • anticonvulsant • antidepressant agents

This article has been cited by other articles:

				P. Ryvlin, A. Montavont, and N. Nighoghossian Optimizing therapy of seizures in stroke patients Neurology, December 26, 2006; 67(12_suppl_4): S3 - S9. [Abstract] [Full Text]

				O. Camilo and L. B. Goldstein Seizures and Epilepsy After Ischemic Stroke Stroke, July 1, 2004; 35(7): 1769 - 1775. [Abstract] [Full Text] [PDF]

				R. J. Traystman, J. A. Klaus, A. C. DeVries, A. B. Shaivitz, and P. D. Hurn Anticonvulsant Lamotrigine Administered on Reperfusion Fails To Improve Experimental Stroke Outcomes Stroke, March 1, 2001; 32(3): 783 - 787. [Abstract] [Full Text] [PDF]

				P. Lipton Ischemic Cell Death in Brain Neurons Physiol Rev, October 1, 1999; 79(4): 1431 - 1568. [Abstract] [Full Text] [PDF]